Cytodyn Inc (CYDY)

[SF Anony]

CTM makes an important point. There's a big difference between a drug trial missing an abstract numerical value in a significance calculation for a Primary End Point, and the *science* behind the drug failing.

Leronlimab's detractors love to hammer on the P-Value of Primary End Points in Leronlimab studies. That's because they have ZERO credible ammunition to train on the science behind what Leronlimab does to the patients in those studies.